Citations

Clear

1031 citation(s) found for "Clark, AS".

Seizure forecasting using minimally invasive, ultra‐long‐term subcutaneous electroencephalography: Individualized intrapatient models
Viana, Pedro F. , Attia, Tal Pal , Duun‐Henriksen, Jonas , Biondi, Andrea , Winston, Joel S. , Martins, Isabel Pavão , Nurse, Ewan S. , Dümpelmann, Matthias , Schulze‐Bonhage, Andreas , Richardson, Mark P. , Brinkmann, Benjamin H. , Pal Attia, Tal , Nasseri, Mona , Duun-Henriksen, Jonas , Biondi, Andrea , Winston, Joel S , Pavão Martins, Isabel , Nurse, Ewan , Dümpelmann, Matthias , Schulze-Bonhage, Andreas , Freestone, Dean R , Kjaer, Troels W , Richardson, Mark P , Brinkmann, Benjamin H , Viana, Pedro F , Freestone, Dean R.

Mayo Clinic

Epilepsia | April 8, 2022 | Volume: 64 | Issue: S4 | Pages: No page available

10.1111/epi.17252 | PMID 35395101 Get It

Abstract Objective One of the most disabling aspects of living with chronic epilepsy is the unpredictability of seizures. Cumulative research in the past decades has advanced our understanding of the dynamics of seizure risk. Technological advances have recently made it possible to record pertinent biological signals, including electroencephalogram (EEG), continuously. We aimed to assess whether patient‐specific seizure forecasting is possible using remote, minimally invasive ultra‐long‐term subcutaneous EEG. Methods We analyzed a two‐center cohort of ultra‐long‐term subcutaneous EEG recordings, including six patients with drug‐resistant focal epilepsy monitored for 46–230 days with median 18 h/day of recorded data, totaling >11 000 h of EEG. Total electrographic seizures identified by visual review ranged from 12 to 36 per patient. Three candidate subject‐specific long short‐term memory network deep learning classifiers were trained offline and pseudoprospectively on preictal (1 h before) and interictal (>1 day from seizures) EEG segments. Performance was assessed relative to a random predictor. Periodicity of the final forecasts was also investigated with autocorrelation. Results Depending on each architecture, significant forecasting performance was achieved in three to five of six patients, with overall mean area under the receiver operating characteristic curve of .65–.74. Significant forecasts showed sensitivity ranging from 64% to 80% and time in warning from 10.9% to 44.4%. Overall, the output of the forecasts closely followed patient‐specific circadian patterns of seizure occurrence. Significance This study demonstrates proof‐of‐principle for the possibility of subject‐specific seizure forecasting using a minimally invasive subcutaneous EEG device capable of ultra‐long‐term at‐home recordings. These results are encouraging for the development of a prospective seizure forecasting trial with minimally invasive EEG.
Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma
Prabhu, Sujit S. , Rao, Ganesh , Laxton, Adrian W. , Fecci, Peter E. , O’Brien, Barbara , Sloan, Andrew E. , Chiang, Veronica , Mohammadi, Alireza M. , Chen, Clark, Sun, David, Sinicrope, Kaylyn, Campian, Jian , Kurz, Sylvia C. , Smith, Kris A. , Tovar-Spinoza, Zulma , Leuthardt, Eric C. , Khasraw, Mustafa , Fecci, Peter E , Groot, John de , Kim, Albert H. , Tatter, Stephen B. , Placantonakis, Dimitris G. , Strowd, Roy E. , Hadjipanayis, Costas G. , Khasraw, Mustafa , Piccioni, David Eric , Williams, Brian J.

Mayo Clinic

Neuro-Oncology Advances | April 6, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdac040 | PMID 35611270 Get It

Abstract Background Treatment options for unresectable new and recurrent glioblastoma remain limited. Laser ablation has demonstrated safety as a surgical approach to treating primary brain tumors. The LAANTERN prospective multicenter registry (NCT02392078) data were analyzed to determine clinical outcomes for patients with new and recurrent IDH wild-type glioblastoma. Methods Demographics, intraprocedural data, adverse events, KPS, health economics, and survival data were prospectively collected and then analyzed on IDH wild-type newly diagnosed and recurrent glioblastoma patients who were treated with laser ablation at 14 US centers between January 2016 and May 2019. Data were monitored for accuracy. Statistical analysis included individual variable summaries, multivariable differences in survival, and median survival numbers. Results A total of 29 new and 60 recurrent IDH wild-type WHO grade 4 glioblastoma patients were treated. Positive MGMT promoter methylation status was present in 5/29 of new and 23/60 of recurrent patients. Median physician-estimated extent of ablation was 91%-99%. Median overall survival (OS) was 9.73 months (95% confidence interval: 5.16, 15.91) for newly diagnosed patients and median post-procedure survival was 8.97 months (6.94, 12.36) for recurrent patients. Median OS for newly diagnosed patients receiving post-LITT chemo/radiation was 16.14 months (6.11, not reached). Factors associated with improved survival were MGMT promoter methylation, adjuvant chemotherapy within 12 weeks, and tumor volume <3 cc. Conclusions Laser ablation is a viable option for patients with new and recurrent glioblastoma. Median OS for IDH wild-type newly diagnosed glioblastoma is comparable to outcomes observed in other tumor resection studies when those patients undergo radiation and chemotherapy following LITT.
National trends in prescription drug expenditures and projections for 2022
Tichy, Eric M. , Hoffman, James M. , Suda, Katie J. , Rim, Matthew H, Tadrous, Mina , Cuéllar, Sandra , Clark, John Spencer , Ward, Jennifer , Schumock, Glen T., Ward, Jennifer

Mayo Clinic

American Journal of Health-System Pharmacy | April 6, 2022 | Volume: 79 | Issue: 14 | Pages: 1158-1172

10.1093/ajhp/zxac102 | PMID 35385103 Get It

Abstract Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2022 in the United States, with a focus on the nonfederal hospital and clinic sectors. Methods Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2022 were reviewed—including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for biosimilars, cancer drugs, generics, COVID-19 pandemic influence, and specialty drugs. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2022 were based on a combination of quantitative analyses and expert opinion. Results In 2021, overall pharmaceutical expenditures in the US grew 7.7% compared to 2020, for a total of $576.9 billion. Utilization (a 4.8% increase), price (a 1.9% increase) and new drugs (a 1.1% increase) drove this increase. Adalimumab was the top drug in terms of overall expenditures in 2021, followed by apixaban and dulaglutide. Drug expenditures were $39.6 billion (a 8.4% increase) and $105.0 billion (a 7.7% increase) in nonfederal hospitals and in clinics, respectively. In clinics and hospitals, new products and increased utilization growth drove growth, with decreasing prices for both sectors acting as an expense restraint. Several new drugs that are likely to influence spending are expected to be approved in 2022. Specialty and cancer drugs will continue to drive expenditures along with the evolution of the COVID-19 pandemic. Conclusion For 2022, we expect overall prescription drug spending to rise by 4.0% to 6.0%, whereas in clinics and hospitals we anticipate increases of 7.0% to 9.0% and 3.0% to 5.0%, respectively, compared to 2021. These national estimates of future pharmaceutical expenditure growth may not be representative of any particular health system because of the myriad of local factors that influence actual spending.
Mapping multiregional image-localized biopsies to MRI habitats reveal biologically significant glioma tissue states and patterns of cellular subpopulations
Curtin, Lee , Bond, Kamila M. , Jackson, Pamela , Hawkins‐Daarud, Andrea , Velez, Sebastian, Shakir, Neha, Urcuyo, Javier , León, Gustavo De , Singleton, Kyle , Langworthy, Jazlynn , Clark-Swanson, Kamala R., Lassiter-Morris, Yvette, Paulson, Lisa, Sereduk, Christopher, Krishna, Chandan , Zimmerman, Richard S. , Patra, Devi Prasad, Smith, Kris A. , Donev, Kliment , Tran, Nhan L. , Hu, Leland , Plaisier, Christopher, Mrugała, Maciej M. , Canoll, Peter , Swanson, Kristin R. , Swanson, Kristin R , Tran, Nhan L , Velez, Sebastian, Shakir, Neha, Leon, Gustavo De, Clark-Swanson, Kamala R., Lassiter-Morris, Yvette, Paulson, Lisa, Sereduk, Chris , Bendok, Bernard R. , Nakaji, Peter , Baxter, Leslie C. , Plaisier, Christopher, Anderson, Alexander R A , Grinband, Jack , Al‐Dalahmah, Osama , Rubin, Joshua B

Mayo Clinic

No container title available | March 26, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2022.03.23.485500 Get It

Abstract Background Magnetic Resonance Imaging (MRI) is the mainstay for neurosurgical oncology but not for informing us about glioma biology. An obstacle to developing MR-based glioma biomarkers is the absence of rigorous correlation between MRI features and glioma biology as assessed in multi-regional biopsies, within and across patients. Methods We directly addressed this obstacle by collating a unique cohort of 202 MRI-localized biopsies from 58 patients. We define a low-dimensional transcriptional pseudotime continuum along which heterogeneous high-grade glioma (HGG) samples organize both within and across patients. Results We observe three polarized transcriptional tissue states: infiltrated brain, immune/inflammatory, and proliferative associated with patterns of cohabitation of cellular subpopulations. The states and deconvolved populations show correlation with enhancement status on T1Gd MRI. Moreover, discrete MRI habitats, regions sharing common imaging features, defined as combinations of high or low signal intensity across multiparametric MRI revealed 14 MRI habitats. We order the MRI habitats according to the average pseudotime on the transcriptional continuum. We find that MRI habitats with low pseudotime (associated with early tumor development and diffusely invaded brain tissue) localized at the periphery of the tumor whilst high pseudotime either proliferative or immune/inflammatory states were towards the core of the lesion. We find that composition of MRI habitats are impacted by MGMT status and patient sex. Conclusion This suggests that ongoing aggregation of MRI-localized biopsies may augment our projection of biology onto MRI habitats to support tracking of the evolution of cellular ecologies within and across each patient’s tumor over time. Key Points Trajectory inference of HGG samples reveals a continuum connecting three polarized tissue states reflecting transitions in cellular population ecologies and gene set enrichment Combining multiparametric MRI features into regional MRI habitats reveal clinically-distinct patterns of cell co-habitation and tissue state MGMT methylation status shifts the cellular patterns of cohabitation within MRI habitats Importance of the Study Regional heterogeneity is a defining characteristic of high-grade glioma (HGG). Mapping the transcriptomic biology of multiregionally sampled MRI-localized biopsies from high-grade gliomas onto a low-dimensional space reveals a continuum between three primary tissue states: infiltrated brain, immune/inflammatory, and proliferative. Each state is associated with distinct cell cohabitation ecologies. Transitions between the tissue states coordinate with changes in tumor composition, revealing potential direct connections between tumor biology shifts and their manifestation on clinical imaging.
Abstract 263: Predictors of Physical Activity Increase among People Enrolled in a Worksite Wellness Center
Diaz-Melean, Carlos M, Rodriguez-Escudero, Juan P., Clark, Matthew M. , Egginton, Jason S. , Oliveros, Estefanía , Somers, Virend K. , Thomas, Randal J. , López-Jiménez, Francisco

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 6 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.6.suppl_1.a263 Get It

Background: Physical activity (PA) prevents cardiovascular (CV) disease and maintains health. It is unclear which factors predict the adoption or maintenance of PA at a worksite wellness center. Methods: To assess the predictors of increase in PA we conducted a retrospective study on 7237 adults attending a worksite wellness center between September 2008 and October 2011. Upon joining the wellness center, participants completed an electronic or paper survey that assessed for the presence of CV risk factors, height, weight, self-perceived health behaviors and psychosocial factors using eleven validated 0-10 point scale. We included 1927 participants who completed the standard survey at the time of enrollment and at 12 months (+/- 90 days). For logistic regression analysis PA increase at 12 months was defined as an increase of ≥2 points of self-reported PA, on a 0 to 10 point scale, or maintenance of a high level of PA at follow up (FU). Results: Mean (SD) age was 38 (11) yr., BMI was 26.93 (6.06) kg/m 2 and 32% were men. From the study sample, 717 (37%) participants increased their PA level or maintained a high level of PA at FU. When comparing people who increased or maintained a high level of PA with the group without improvement or a decline in PA, there were differences in age and BMI: age [39 (11) vs. 38 (11) yr.; p=0.04] and BMI [27.37 (5.92) vs. 26.68 (5.92) kg/m 2 ; p=0.024]. The Table reports the results of the multivariate logistic regression model. While CV risk factors (tobacco use, hyperglycemia/diabetes mellitus, and high blood cholesterol), perceived stress level and self-perception of being overweight were not significant predictors of increase PA, low muscular strength and flexibility and interactions with close friends were significantly associated with PA. Conclusion: A significant proportion of people, over one-third, enrolled in a wellness center increase their PA level or maintain high levels of PA at 12 months after enrollment. Increasing age and BMI, and a measure of social support; interaction with close friends, and perceived muscular strength and flexibility, predict increase in PA. Presence of CV risk factors do not predict increase in PA. Tailoring programs to address these domains may help younger, less fit, and those with less social support improve their PA level.
A Preliminary Report of Network Electroencephalographic Measures in Primary Progressive Apraxia of Speech and Aphasia
Utianski, Rene L. , Caviness, John N., Duffy, Joseph R. , Clark, Heather M. , Whitwell, Jennifer L. , Josephs, Keith A. , Duffy, Joseph R , Clark, Heather M , Utianski, Rene L , Botha, Hugo , Worrell, Gregory A.

Mayo Clinic

Brain Sciences | March 13, 2022 | Volume: 12 | Issue: 3 | Pages: 378

10.3390/brainsci12030378 | PMID 35326334 Get It

The objective of this study was to characterize network-level changes in nonfluent/agrammatic Primary Progressive Aphasia (agPPA) and Primary Progressive Apraxia of Speech (PPAOS) with graph theory (GT) measures derived from scalp electroencephalography (EEG) recordings. EEGs of 15 agPPA and 7 PPAOS patients were collected during relaxed wakefulness with eyes closed (21 electrodes, 10–20 positions, 256 Hz sampling rate, 1–200 Hz bandpass filter). Eight artifact-free, non-overlapping 1024-point epochs were selected. Via Brainwave software, GT weighted connectivity and minimum spanning tree (MST) measures were calculated for theta and upper and lower alpha frequency bands. Differences in GT and MST measures between agPPA and PPAOS were assessed with Wilcoxon rank-sum tests. Of greatest interest, Spearman correlations were computed between behavioral and network measures in all frequency bands across all patients. There were no statistically significant differences in GT or MST measures between agPPA and PPAOS. There were significant correlations between several network and behavioral variables. The correlations demonstrate a relationship between reduced global efficiency and clinical symptom severity (e.g., parkinsonism, AOS). This preliminary, exploratory study demonstrates potential for EEG GT measures to quantify network changes associated with degenerative speech–language disorders.
Orofacial Muscle Strength across the Dysarthrias
Clark, Heather M. , Duffy, Joseph R. , Hanley, Holly , Solomon, Nancy Pearl , Strand, Edythe A. , Hanley, Holly , Solomon, Nancy Pearl , Clark, Heather M , Duffy, Joseph R

Mayo Clinic

Brain Sciences | March 10, 2022 | Volume: 12 | Issue: 3 | Pages: 365

10.3390/brainsci12030365 | PMID 35326321 Get It

This study compared orofacial muscle strength between normal and dysarthric speakers and across types of dysarthria, and examined correlations between strength and dysarthria severity. Participants included 79 speakers with flaccid, spastic, mixed spastic–flaccid, ataxic, or hypokinetic dysarthria and 33 healthy controls. Maximum pressure generation (Pmax) by the tongue, lips, and cheeks represented strength. Pmax was lower for speakers with mixed spastic–flaccid dysarthria for all tongue and lip measures, as well as for speakers with flaccid or spastic dysarthria for anterior tongue elevation and lip compression. Anterior tongue elevation and cheek compression tended to be lower than normal for the hypokinetic group. Pmax did not differ significantly between controls and speakers with ataxic dysarthria on any measure. Correlations were generally weak between dysarthria severity and orofacial weakness but were stronger in the dysarthria groups with more prominent orofacial weakness. The results generally support predictions that orofacial weakness accompanies flaccid and/or spastic dysarthria but not ataxic dysarthria. The findings support including type of dysarthria as a variable of interest when examining orofacial weakness in motor speech disorders.
Abstract GS4-02: Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial
Kyalwazi, Beverly , Olopade, Olufunmilayo, Chien, A. Jo , Forero‐Torres, Andres , Ellis, Erin M. , Albain, Kathy S. , Haley, Barbara , Elias, A. , Clark, Amy S. , Nanda, Rita , Yung, Rachel L. , Edmiston, Kristen K., Viscusi, Rebecca K., Northfelt, Donald W. , Khan, Qamar J. , Sanil, Ashish, Asare, Smita , Wilson, Amy , Hirst, Gillian L. , Melisko, Michelle , Perlmutter, Jane , Rugo, Hope, Symmans, Fraser, Veer, Laura van ‘t , Berry, Donald A. , Hirst, Gillian L , Yau, Christina , Olopade, Olufunmilayo I. , Wallace, Anne M. , Pusztai, Lajos , Ellis, Erin, Blaes, Anne , Boughey, Judy C. , Isaacs, Claudine , Han, Hyo S , Tripathy, Debu , Berry, Scott , Hylton, Nola M. , Symmans, W. Fraser , Veer, Laura J. van’t , Esserman, Laura J.

Mayo Clinic

Cancer Research | March 8, 2022 | Volume: 82 | Issue: 4_Supplement | Pages: GS4-02-GS4-02

10.1158/1538-7445.sabcs21-gs4-02 Get It

Abstract Background Transcriptomic immune-related gene signatures have been associated with achievement of pathologic complete response (pCR) and prognosis in the neoadjuvant setting. I-SPY 2 is a multicenter, phase 2 platform trial using response-adaptive randomization within subtypes defined by receptor status (HR/HER2) and MammaPrint (MP) risk to evaluate novel agents as neoadjuvant therapy for women with high-risk breast cancer. Given racial disparities in mortality from breast cancer and the paucity of racial demographic data from clinical trials, we aimed to evaluate the association between racial groups and baseline characteristics, including expression-based subtypes and immune signatures, treatment response, and prognosis of patients enrolled in the I-SPY 2 TRIAL. Methods Our study population included 990 I-SPY 2 patients. 15 patients identified as part of a racial group with <10 patients enrolled in the trial and were excluded from analysis. Pre-treatment expression data was available for 971 patients. Follow-up data was available for 907 patients; median follow-up time of 4.4 yrs. Chi-square test was used to assess associations between racial groups and pre-treatment SBR grade, HR/HER2 defined subtypes, intrinsic subtype (defined by BluePrint 80-gene molecular subtyping) and residual cancer burden (RCB) class. Logistic regression was used to evaluate race association with pCR. Cox proportional hazard modeling was used to assess the association between racial groups and event free survival (EFS) in a univariate setting, adjusting for pCR status. Association between racial groups and 28 expression signatures related to immune, proliferation, ER and HER2 pathway was analyzed using ANOVA with post-hoc Tukey test in the overall population and in each receptor subtype. Results Of 975 patients included in our analysis, 787 (81%) were White, 68 (7%) were Asian, and 120 (12%) were Black or African American. No significant associations between race and pre-treatment SBR grade (p=0.49), HR/HER2 defined subtypes (p=0.09), or expression-based subtypes (p=0.25) were observed. pCR rates do not significantly differ by racial groups (Odds ratio of pCR relative to White: 1.00 for Asian and 0.89 for Black or African American); and no significant differences in RCB class distribution by race was observed (p=0.88). Event free survival was not associated with patient racial group in a univariate Cox model (Hazard ratio relative to White: 1.10, p=0.73 for Asian and 1.37, p=0.13 for Black or African American). Among the 28 expression signatures evaluated, four were differentially expressed among racial groups within the overall population (F-test p<0.05): IFN module, B cell signature, Dendritic cell signature, and Mitotic score. Pairwise comparisons between racial groups with post-hoc Tukey test identified significant differences in IFN module expression between Black or African American vs. White (p=0.019) and Dendritic cell signature expression between Asian vs White (p=0.047). Among patients in the TNBC subtype, three signatures (dendritic cell signature, macrophage signature and ERBB2 module) were differentially expressed between Black or African American and White patients (p=0.002, 0.016 and 0.007). Conclusion Our analysis demonstrates that among women with high risk breast cancer, race does not affect subtype specific response rates nor event free survival. Distribution of subtypes previously shown to be associated with pCR in the I-SPY2 trial did not significantly differ among racial groups indicating race is less likely than tumor biology to predict response. The decreased expression of immune signatures observed in Black or African American women with TNBC suggests possible differential sensitivity to immunotherapy plus combination chemotherapy. Tumor immune multiplex studies are underway to further investigate. Citation Format: Beverly Kyalwazi, Christina Yau, Olufunmilayo Olopade, A. Jo Chien, Anne Wallace, Andres Forero-Torres, Lajos Pusztai, Erin Ellis, Kathy Albain, Anne Blaes, Barbara Haley, Judy Boughey, Anthony Elias, Amy Clark, Claudine Isaacs, Rita Nanda, Hyo Han, Rachel Yung, Debu Tripathy, Kristen Edmiston, Rebecca Viscusi, Donald Northfelt, Qamar Khan, Ashish Sanil, Scott Berry, Smita Asare, Amy Wilson, Gillian Hirst, Nola Hylton, Michelle Melisko, Jane Perlmutter, Hope Rugo, Fraser Symmans, Laura van ‘t Veer, Donald Berry, Laura Esserman. Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr GS4-02.
Predicting malignant pleural effusion during diagnostic pleuroscopy with biopsy: A prospective multicentre study
Grosu, Horiana B. , Kern, Ryan , Maldonado, Fabien , Casal, Roberto F. , Eapen, Georgie A. , Ost, David E. , Jiménez, Carlos , Frangopoulos, Frangiskos, Sabath, Bruce F. , Vakil, Erik , Schwalk, Audra, Marcoux, Mathieu , Sagar, Ala-Eddin S. , Nasim, Faria, Lin, Julie , Salahudin, Moiz, Arain, Hasan Muhammad, Noor, Laila , Montanez, Diana, Stewart, John , Mullon, John J., Porfyridis, Ilias, Casal, Roberto , Ost, David E , Vakil, Erik , Salahudin, Moiz , Mullon, John, Kern, R , Andersen, Clark R. , Li, Liang , Jimenez, Carlos, Michael, Michalis

Mayo Clinic

Respirology | February 18, 2022 | Volume: 27 | Issue: 5 | Pages: 350-356

10.1111/resp.14232 | PMID 35178828 Get It

AbstractBackground and objectivePleuroscopy with pleural biopsy has a high sensitivity for malignant pleural effusion (MPE). Because MPEs tend to recur, concurrent diagnosis and treatment of MPE during pleuroscopy is desired. However, proceeding directly to treatment at the time of pleuroscopy requires confidence in the on‐site diagnosis. The study's primary objective was to create a predictive model to estimate the probability of MPE during pleuroscopy.MethodsA prospective observational multicentre cohort study of consecutive patients undergoing pleuroscopy was conducted. We used a logistic regression model to evaluate the probability of MPE with relation to visual assessment, rapid on‐site evaluation (ROSE) of touch preparation and presence of pleural nodules/masses on computed tomography (CT). To assess the model's prediction accuracy, a bootstrapped training/testing approach was utilized to estimate the cross‐validated area under the receiver operating characteristic curve.ResultsOf the 201 patients included in the study, 103 had MPE. Logistic regression showed that higher level of malignancy on visual assessment is associated with higher odds of MPE (OR = 34.68, 95% CI = 9.17–131.14,p < 0.001). The logistic regression also showed that higher level of malignancy on ROSE of touch preparation is associated with higher odds of MPE (OR = 11.63, 95% CI = 3.85–35.16,p < 0.001). Presence of pleural nodules/masses on CT is associated with higher odds of MPE (OR = 6.61, 95% CI = 1.97–22.1,p = 0.002). A multivariable logistic regression model of final pathologic status with relation to visual assessment, ROSE of touch preparation and presence of pleural nodules/masses on CT had a cross‐validated AUC of 0.94 (95% CI = 0.91–0.97).ConclusionA prediction model using visual assessment, ROSE of touch preparation and CT scan findings demonstrated excellent predictive accuracy for MPE. Further validation studies are needed to confirm our findings.
Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease
Alayo, Quazim A. , Fenster, Marc, Glassner, Kerri , Llano, Ernesto M. , Clark‐Snustad, Kindra , Kwapisz, Lukasz , Yarur, Andrés , Cohen, Benjamin L, Ciorba, Matthew A. , Thomas, Deborah A. , Lee, Scott D. , Loftus, Edward V. , Fudman, David , Abraham, Bincy , Deepak, Parakkal , Colombel, J F. , Deepak, Parakkal , Loftus, Edward V , Yarur, Andres J , Altayar, Osama , Patel, Anish A , Cohen, Benjamin L, Colombel, Jean‐Frédéric

Mayo Clinic

Crohn's & Colitis 360 | February 9, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/crocol/otac002 | PMID 35310082 Get It

Abstract Background Combining biologics and small molecules could potentially overcome the plateau of drug efficacy in inflammatory bowel disease (IBD). We conducted a systematic review and meta-analysis to assess the safety and effectiveness of dual biologic therapy (DBT), or small molecule combined with a biologic therapy (SBT) in IBD patients. Methods We searched MEDLINE, EMBASE, Scopus, Web of Science, Cochrane Database of Systematic Reviews, and Clinical trials.gov until November 3, 2020, including studies with 2 or more IBD patients on DBT or SBT. Main outcome was safety assessed as pooled rates of adverse events (AEs) and serious AEs (SAEs) for each combination. Effectiveness was reported as pooled rates of clinical, endoscopic, and/or radiographic response and remission. The certainty of evidence was rated according to the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) framework. Results Of the 3688 publications identified, 13 studies (1 clinical trial, 12 observational studies) involving 266 patients on 7 different combinations were included. Median number of prior biologics ranged from 0 to 4, and median duration of follow-up was 16–68 weeks. Most common DBT and SBT were vedolizumab (VDZ) with anti-tumor necrosis factor (aTNF, n = 56) or tofacitinib (Tofa, n = 57), respectively. Pooled rates of SAE for these were 9.6% (95% confidence interval [CI], 1.5–21.4) for VDZ-aTNF and 1.0% (95% CI, 0.0–7.6) for Tofa-VDZ. The overall certainty of evidence was very low due to the observational nature of the studies, and very serious imprecision and inconsistency. Conclusions DBT or SBT appears to be generally safe and may be effective in IBD patients, but the evidence is very uncertain.